Gary W. Herschman, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Newark office, was featured in Irving Levin Associates, Inc.’s Health Care M&Ablog, in “Hot Healthcare Sectors for Investment, Growth & Consolidation in 2020,” by Lisa Phillips.
Following is an excerpt:
Every year, starting in November, the crystal balls come out and the prognostications begin. What will the new year bring? Who or what will make out better and who or what will not? We talked with Gary Herschman, a member of Epstein Becker Green’s Healthcare and Life Sciences practice, about the healthcare sectors he and his firm are watching in 2020. Here are their predictions for 2020.
Health Care M&A: What do you see as the biggest themes in the healthcare industry this year? There are a lot of moving parts, from the discovery of new drugs to the shifting attention to post-acute care.
Gary Herschman: We see three key “drivers” of health industry transformation that are already underway. First, there’s the national imperative of reducing the cost of health care, via disease prevention and detection, and providing more efficient care in ambulatory and retail settings.
Second, technologies which enhance disease prevention, detection and cost-effective treatment have made extraordinary advances. For example, artificial intelligence (AI)-driven diagnosis and treatment, virtual care, electronic medical record (EMR) systems, medical devices, gene therapy, and precision medicine.
Finally, inevitably, there’s the reality of the aging baby-boomer population, with tens of millions of Americans entering into their 70s and 80s.